Solve Therapeutics

Solve Therapeutics is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) and precision diagnostics for solid tumors. The company builds targeted cancer therapies designed to improve safety and efficacy by combining highly selective antibodies with its proprietary CloakLink platform, a hydrophilic linker system engineered to deliver payloads more efficiently and reduce off-target toxicity.

Its pipeline includes multiple clinical-stage ADCs with differentiated designs, optimized for stability in circulation and controlled drug release within tumor cells. Solve Therapeutics also integrates companion diagnostic tools to enable precise patient selection, an approach that supports more effective treatment decisions and aligns with the industry shift toward personalized oncology.

Backed by major life-science investors, the company advances its programs through a platform that spans early discovery to clinical development, supported by internal expertise in targeted radiochemistry, chemistry-based design, and translational biology. Solve Therapeutics positions itself at the intersection of technology and cancer drug development, aiming to produce best-in-class therapies for hard-to-treat solid tumors.

Keywords: antibody-drug conjugates, oncology, precision diagnostics, targeted therapies, solid tumors, biotechnology, CloakLink platform